Edition:
United States

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

77.68USD
14 Dec 2017
Change (% chg)

$-3.40 (-4.19%)
Prev Close
$81.08
Open
$81.00
Day's High
$81.30
Day's Low
$77.00
Volume
58,098
Avg. Vol
35,826
52-wk High
$100.99
52-wk Low
$13.11

Select another date:

Wed, Dec 6 2017

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196

* Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196 in patients with heterozygous familial hypercholesterolemia

BRIEF-Madrigal Pharmaceuticals reports qtrly loss per share $0.69‍​

* Madrigal Pharmaceuticals reports 2017 second quarter financial results

BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH

* Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH

BRIEF-Madrigal Pharma announces $35 million private placement offering

* Madrigal pharmaceuticals announces $35 million private placement offering

Select another date: